vs
Side-by-side financial comparison of Amphastar Pharmaceuticals, Inc. (AMPH) and PRA GROUP INC (PRAA). Click either name above to swap in a different company.
PRA GROUP INC is the larger business by last-quarter revenue ($333.4M vs $183.1M, roughly 1.8× Amphastar Pharmaceuticals, Inc.). PRA GROUP INC runs the higher net margin — 17.0% vs 13.3%, a 3.6% gap on every dollar of revenue. On growth, PRA GROUP INC posted the faster year-over-year revenue change (13.7% vs -1.8%). Amphastar Pharmaceuticals, Inc. produced more free cash flow last quarter ($24.6M vs $-90.4M). Over the past eight quarters, PRA GROUP INC's revenue compounded faster (14.2% CAGR vs 3.2%).
Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company. It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products.
PRA Group, Inc. is a publicly traded debt buyer and debt collection company based in Norfolk, Virginia. The company buys delinquent consumer debt from credit card issuers and other financial institutions at a discount and pursues collection of the full debt owed. Founded in 1996, PRA Group employs more than 3200 people in 18 countries.
AMPH vs PRAA — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $183.1M | $333.4M |
| Net Profit | $24.4M | $56.5M |
| Gross Margin | 46.8% | — |
| Operating Margin | 19.4% | 37.7% |
| Net Margin | 13.3% | 17.0% |
| Revenue YoY | -1.8% | 13.7% |
| Net Profit YoY | -35.7% | 206.3% |
| EPS (diluted) | $0.51 | $1.47 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $183.1M | $333.4M | ||
| Q3 25 | $191.8M | $311.1M | ||
| Q2 25 | $174.4M | $287.7M | ||
| Q1 25 | $170.5M | $269.6M | ||
| Q4 24 | $186.5M | $293.2M | ||
| Q3 24 | $191.2M | $281.5M | ||
| Q2 24 | $182.4M | $284.2M | ||
| Q1 24 | $171.8M | $255.6M |
| Q4 25 | $24.4M | $56.5M | ||
| Q3 25 | $17.4M | $-407.7M | ||
| Q2 25 | $31.0M | $42.4M | ||
| Q1 25 | $25.3M | $3.7M | ||
| Q4 24 | $38.0M | $18.5M | ||
| Q3 24 | $40.4M | $27.2M | ||
| Q2 24 | $37.9M | $21.5M | ||
| Q1 24 | $43.2M | $3.5M |
| Q4 25 | 46.8% | — | ||
| Q3 25 | 51.4% | — | ||
| Q2 25 | 49.6% | — | ||
| Q1 25 | 50.0% | — | ||
| Q4 24 | 46.5% | — | ||
| Q3 24 | 53.3% | — | ||
| Q2 24 | 52.2% | — | ||
| Q1 24 | 52.4% | — |
| Q4 25 | 19.4% | 37.7% | ||
| Q3 25 | 13.2% | -101.4% | ||
| Q2 25 | 24.2% | 29.6% | ||
| Q1 25 | 21.9% | 27.7% | ||
| Q4 24 | 24.2% | 32.1% | ||
| Q3 24 | 29.8% | 32.0% | ||
| Q2 24 | 30.3% | 31.4% | ||
| Q1 24 | 27.9% | 26.0% |
| Q4 25 | 13.3% | 17.0% | ||
| Q3 25 | 9.0% | -131.0% | ||
| Q2 25 | 17.8% | 14.7% | ||
| Q1 25 | 14.8% | 1.4% | ||
| Q4 24 | 20.4% | 6.3% | ||
| Q3 24 | 21.1% | 9.6% | ||
| Q2 24 | 20.8% | 7.6% | ||
| Q1 24 | 25.1% | 1.4% |
| Q4 25 | $0.51 | $1.47 | ||
| Q3 25 | $0.37 | $-10.43 | ||
| Q2 25 | $0.64 | $1.08 | ||
| Q1 25 | $0.51 | $0.09 | ||
| Q4 24 | $0.74 | $0.47 | ||
| Q3 24 | $0.78 | $0.69 | ||
| Q2 24 | $0.73 | $0.54 | ||
| Q1 24 | $0.81 | $0.09 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $282.8M | $104.4M |
| Total DebtLower is stronger | $608.7M | — |
| Stockholders' EquityBook value | $788.8M | $979.9M |
| Total Assets | $1.6B | $5.1B |
| Debt / EquityLower = less leverage | 0.77× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $282.8M | $104.4M | ||
| Q3 25 | $276.2M | $107.5M | ||
| Q2 25 | $231.8M | $131.6M | ||
| Q1 25 | $236.9M | $128.7M | ||
| Q4 24 | $221.6M | $105.9M | ||
| Q3 24 | $250.5M | $141.1M | ||
| Q2 24 | $217.8M | $118.9M | ||
| Q1 24 | $289.6M | $108.1M |
| Q4 25 | $608.7M | — | ||
| Q3 25 | $608.6M | — | ||
| Q2 25 | $607.7M | — | ||
| Q1 25 | $603.9M | — | ||
| Q4 24 | $601.6M | — | ||
| Q3 24 | $596.4M | — | ||
| Q2 24 | $586.9M | — | ||
| Q1 24 | $594.0M | — |
| Q4 25 | $788.8M | $979.9M | ||
| Q3 25 | $776.7M | $928.5M | ||
| Q2 25 | $757.5M | $1.3B | ||
| Q1 25 | $751.3M | $1.2B | ||
| Q4 24 | $732.3M | $1.1B | ||
| Q3 24 | $727.7M | $1.2B | ||
| Q2 24 | $713.3M | $1.1B | ||
| Q1 24 | $672.4M | $1.1B |
| Q4 25 | $1.6B | $5.1B | ||
| Q3 25 | $1.7B | $5.0B | ||
| Q2 25 | $1.6B | $5.4B | ||
| Q1 25 | $1.6B | $5.1B | ||
| Q4 24 | $1.6B | $4.9B | ||
| Q3 24 | $1.5B | $4.9B | ||
| Q2 24 | $1.5B | $4.7B | ||
| Q1 24 | $1.6B | $4.5B |
| Q4 25 | 0.77× | — | ||
| Q3 25 | 0.78× | — | ||
| Q2 25 | 0.80× | — | ||
| Q1 25 | 0.80× | — | ||
| Q4 24 | 0.82× | — | ||
| Q3 24 | 0.82× | — | ||
| Q2 24 | 0.82× | — | ||
| Q1 24 | 0.88× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $32.9M | $-85.5M |
| Free Cash FlowOCF − Capex | $24.6M | $-90.4M |
| FCF MarginFCF / Revenue | 13.4% | -27.1% |
| Capex IntensityCapex / Revenue | 4.5% | 1.4% |
| Cash ConversionOCF / Net Profit | 1.35× | -1.51× |
| TTM Free Cash FlowTrailing 4 quarters | $121.2M | $-169.4M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $32.9M | $-85.5M | ||
| Q3 25 | $52.6M | $-10.1M | ||
| Q2 25 | $35.6M | $-12.9M | ||
| Q1 25 | $35.1M | $-52.6M | ||
| Q4 24 | $29.0M | $-94.6M | ||
| Q3 24 | $60.0M | $-35.0M | ||
| Q2 24 | $69.1M | $-29.5M | ||
| Q1 24 | $55.3M | $-73.0M |
| Q4 25 | $24.6M | $-90.4M | ||
| Q3 25 | $47.2M | $-11.3M | ||
| Q2 25 | $25.0M | $-14.2M | ||
| Q1 25 | $24.4M | $-53.5M | ||
| Q4 24 | $16.6M | $-98.6M | ||
| Q3 24 | $46.2M | $-36.1M | ||
| Q2 24 | $63.1M | $-30.8M | ||
| Q1 24 | $46.5M | $-73.5M |
| Q4 25 | 13.4% | -27.1% | ||
| Q3 25 | 24.6% | -3.6% | ||
| Q2 25 | 14.3% | -4.9% | ||
| Q1 25 | 14.3% | -19.8% | ||
| Q4 24 | 8.9% | -33.6% | ||
| Q3 24 | 24.1% | -12.8% | ||
| Q2 24 | 34.6% | -10.8% | ||
| Q1 24 | 27.1% | -28.8% |
| Q4 25 | 4.5% | 1.4% | ||
| Q3 25 | 2.8% | 0.4% | ||
| Q2 25 | 6.1% | 0.4% | ||
| Q1 25 | 6.3% | 0.3% | ||
| Q4 24 | 6.7% | 1.4% | ||
| Q3 24 | 7.2% | 0.4% | ||
| Q2 24 | 3.3% | 0.5% | ||
| Q1 24 | 5.1% | 0.2% |
| Q4 25 | 1.35× | -1.51× | ||
| Q3 25 | 3.03× | — | ||
| Q2 25 | 1.15× | -0.30× | ||
| Q1 25 | 1.39× | -14.37× | ||
| Q4 24 | 0.76× | -5.13× | ||
| Q3 24 | 1.48× | -1.29× | ||
| Q2 24 | 1.82× | -1.37× | ||
| Q1 24 | 1.28× | -21.01× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
PRAA
| GB | $170.1M | 51% |
| Other | $163.3M | 49% |
